Ignite Creation Date:
2024-05-05 @ 5:14 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00419367
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2022-09-22
First Post:
2007-01-05
Brief Title:
Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma 0683-042
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
Compassionate Use of Vorinostat MK0683 for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma
Status:
NO_LONGER_AVAILABLE
Status Verified Date:
2022-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In an effort to allow patients continued access to vorinostat outside of the base study patients that are actively receiving study medication will discontinue from this study and receive vorinostat via another method supported by the SPONSOR eg Named Patient Program NPP For those institutions that do not allow receipt of an investigational therapy outside of a clinical trial patients that are actively receiving study medication and
continue to meet eligibility will transition to an extension phase of the study and the base study will be closed
The extension phase will begin as soon as the protocol amendment is implemented
continue to meet eligibility will transition to an extension phase of the study and the base study will be closed
The extension phase will begin as soon as the protocol amendment is implemented
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2006-003879-12 | EUDRACT_NUMBER | None | None |
| MK0683-042 | None | None | None |
| 2006_540 | None | None | None |